Edition:
United Kingdom

Wockhardt Ltd (WCKH.NS)

WCKH.NS on National Stock Exchange of India

392.15INR
10:24am GMT
Change (% chg)

Rs2.55 (+0.65%)
Prev Close
Rs389.60
Open
Rs391.70
Day's High
Rs401.30
Day's Low
Rs388.45
Volume
906,772
Avg. Vol
1,411,526
52-wk High
Rs852.65
52-wk Low
Rs380.35

Latest Key Developments (Source: Significant Developments)

India's Wockhardt Dec-Quarter Consol Net Loss Widens
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Wockhardt Ltd ::DEC QUARTER CONSOL NET LOSS 711.1 MILLION RUPEES VERSUS LOSS OF 407.6 MILLION RUPEES LAST YEAR.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 10.46 BILLION RUPEES VERSUS 10.05 BILLION RUPEES LAST YEAR.  Full Article

Wockhardt Gets U.S. FDA Approval For Leukemia Drug
Monday, 21 Jan 2019 

Jan 21 (Reuters) - Wockhardt Ltd ::WOCKHARDT RECEIVES US FDA APPROVAL FOR LEUKEMIA DRUG.CO WILL BE LAUNCHING PRODUCT IN THE UNITED STATES, IN A SHORT PERIOD OF TIME.PRODUCT IS BEING MANUFACTURED AT A CONTRACT MANUFACTURING FACILITY, BASED NEAR HYDERABAD, INDIA.  Full Article

India's Wockhardt Ltd March Qtr Consol Loss Narrows
Friday, 4 May 2018 

May 4 (Reuters) - Wockhardt Ltd ::MARCH QUARTER CONSOL NET LOSS 1.55 BILLION RUPEES VERSUS LOSS OF 1.75 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 10.18 BILLION RUPEES VERSUS 8.64 BILLION RUPEES LAST YEAR.SAYS CO APPROVED ISSUANCE OF NCDS ON PRIVATE PLACEMENT BASIS UP TO 12 BILLION RUPEES.SAYS APPROVED RAISING FUNDS OF UP TO 15 BILLION RUPEES.  Full Article

India's Wockhardt posts Sept-qtr consol loss
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Wockhardt Ltd ::Sept quarter consol net loss 33.3 million rupees versus profit of 170.2 million rupees last year.Sept quarter consol revenue from operations 10.22 billion rupees versus 10.65 billion rupees last year.  Full Article

Wockhardt gets U.S. FDA approval for antibiotic injection
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Wockhardt Ltd :Says Wockhardt receives US FDA approval for antibiotic injection.Says is expected to launch this product in United States, soon.Says product is being manufactured at a contract manufacturing facility, based near Milan, Italy.Says received approval from US FDA for an ANDA for 1gm, and 2gm injections of Oxacillin.  Full Article